Updated and new ASCIA HAE resources
The ASCIA Hereditary Angioedema (HAE) Position Paper and Management Plan have been updated and are now available on the ASCIA website: www.allergy.org.au/hp/papers/hereditary-angioedema
The urgent updating of these documents is due to Takhzyro® (lanadelumab) being PBS listed for HAE from 1st December 2021.
We have also taken this opportunity to make other product related changes, including:
- Removal of the product name ‘Firazyr’ as the current product is generic ‘Icatibant’.
- A statement regarding Danazol (Azol) being discontinued in January 2020 in Australia.
- Replacing the Berinert® order form with an updated version on page 25.
- Updating of the ASCIA HAE Management Plan on page 23 to include Takhzyro® (lanadelumab) and remove the product name ‘Firazyr’.
A new ASCIA HAE Frequently Asked Questions (FAQ) for patients, consumers and carers has been developed in October 2021 and is available on the ASCIA website www.allergy.org.au/patients/immunodeficiencies/hae